Xiansheng Pharmaceutical announced that the company previously reached a strategic cooperation with Ruiyang Biotech to obtain exclusive commercial rights from Yingmule in Greater China. On September 3, 2026, culevizumab injection was approved by the State Drug Administration for marketing in China to prevent lower respiratory infections caused by RSV in newborns and infants. The critical phase III study showed 85.32% protective efficacy 150 days after administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.